Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment

被引：0
|
作者：
Georg Feldmann
Peter Brossart
Marie von Lilienfeld-Toal
机构：
[1] University Hospital of Bonn,Department of Internal Medicine 3, Center of Integrated Oncology (CIO) Cologne
[2] Jena University Hospital,Bonn
来源：
Annals of Hematology | 2013年 / 92卷
关键词：
White Blood Cell Count; Lenalidomide; Myelodysplastic Syndrome; Hydroxyurea; Azacitidine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1577 / 1579
页数：2
相关论文
共 50 条
  • [31] Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome
    Hashimoto, Miki
    Itonaga, Hidehiro
    Nannya, Yasuhito
    Taniguchi, Hirokazu
    Fukuda, Yuichi
    Furumoto, Takafumi
    Fujioka, Machiko
    Kasai, Sachie
    Taguchi, Masataka
    Taniguchi, Hiroaki
    Sato, Shinya
    Sawayama, Yasushi
    Atogami, Sunao
    Iwasaki, Keisuke
    Hata, Tomoko
    Soda, Hiroshi
    Moriuchi, Yukiyoshi
    Nakata, Koh
    Ogawa, Seishi
    Miyazaki, Yasushi
    INTERNAL MEDICINE, 2020, 59 (08) : 1081 - 1086
  • [32] Azacitidine-induced pyoderma gangrenosum at injection sites in a patient with myelodysplastic syndrome
    Roy, C.
    Adam, J. P.
    Morin, F.
    Lemieux-Blanchard, E.
    Doucet, S.
    Friedmann, D.
    Belisle, A.
    Charpentier, D.
    CURRENT ONCOLOGY, 2018, 25 (01) : E103 - E105
  • [33] Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome
    Iltar, Utku
    Alhan, Fadime Nurcan
    Vural, Ece
    Atas, Unal
    Sozel, Hasan
    Dogan, Omer
    Boduroglu, Ahmet
    Yucel, Orhan Kemal
    Salim, Ozan
    Undar, Levent
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 500 - 503
  • [34] Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome
    Kitamura, Hiroaki
    Miyahara, Koichi
    Kubota, Yasushi
    Tomimasu, Rika
    Kimura, Shinya
    Miyahara, Masaharu
    EJHAEM, 2021, 2 (03): : 653 - 654
  • [35] Azacitidine-induced pyoderma gangrenosum at injection sites in a patient with myelodysplastic syndrome
    Morin, Frederique
    Friedmann, Dominique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB54 - AB54
  • [36] Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
    Edlin, R.
    Connock, M.
    Tubeuf, S.
    Round, J.
    Fry-Smith, A.
    Hyde, C.
    Greenheld, W.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 69 - 74
  • [37] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Gardin, Claude
    Itzykson, Raphael
    Thepot, Sylvain
    Dreyfus, Francois
    Rauzy, Odile Beyne
    Recher, Christian
    Ades, Lionel
    Quesnel, Bruno
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3322 - 3327
  • [38] OUTCOME OF 5-AZACITIDINE AND DECITABINE TREATMENT IN ELDERLY PATIENTS WITH MYELODYSPLASTIC SYNDROME
    Nam, S.
    Lim, T.
    Kim, B.
    HAEMATOLOGICA, 2013, 98 : 588 - 588
  • [39] Outcome of 5-Azacitidine and Decitabine Treatment in Elderly Patients with Myelodysplastic Syndrome
    Nam, Seung-Hyun
    Lim, Taekyu
    Kim, Bong-Seog
    BLOOD, 2012, 120 (21)
  • [40] Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure
    Lin, Karen
    Reljic, Tea
    Kumar, Ambuj
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2010, 116 (21) : 1199 - 1200
12345